Journal of Current Glaucoma Practice

Register      Login

VOLUME 7 , ISSUE 2 ( May-August, 2013 ) > List of Articles


Current Concepts in the Biochemical Mechanisms of Glaucomatous Neurodegeneration

Syed Shoeb Ahmad, Shuaibah Abdul Ghani, Theodora Hemalata Rajagopal

Keywords : Glaucoma, Biochemical, Neural, Degeneration

Citation Information : Shoeb Ahmad S, Abdul Ghani S, Hemalata Rajagopal T. Current Concepts in the Biochemical Mechanisms of Glaucomatous Neurodegeneration. J Curr Glaucoma Pract 2013; 7 (2):49-53.

DOI: 10.5005/jp-journals-10008-1137

License: CC BY-NC 4.0

Published Online: 01-12-2018

Copyright Statement:  Copyright © 2013; The Author(s).


Glaucoma is now regarded as a neurodegenerative disorder. A number of theories including the mechanical and vascular models have been used to explain the pathogenesis of glaucoma. However, there is now increasing evidence of biochemical molecules which may play a part in it's causation. These biochemical mechanisms include the role of excitatory aminoacids, caspases, protein kinases, oxygen free radicals, nitric oxide, TNF-alpha, neurotrophins and metalloproteins. This paper reviews these new developments which form the biochemical basis of glaucomatous neural degeneration.

PDF Share
  1. Nilforushan N. Neuroprotection in glaucoma. J Ophthalmic Vis Res 2012 Jan;7(1):91-93.
  2. Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma? Arch Ophthalmol 1999 Nov;117(11):1540-1544.
  3. Bautista RD. Glaucomatous neurodegeneration and the concept of neuroprotection. Int Ophthalmol Clin 1999;39(3):57-70.
  4. Osborne NN, Chidlow G, Nash MS, Wood JP. The potential of neuroprotection in glaucoma treatment. Curr Opin Ophthalmol 1999 Apr;10(2):82-92.
  5. Levin LA. Intrinsic survival mechanisms for retinal ganglion cells. Eur J Ophthalmol 1999 Jan-Mar;9 Suppl 1:12S-16S.
  6. Kim TW, Kang KB, Choung HK, Park KH, Kim DM. Elevated glutamate levels in the vitreous body of an in vivo model of optic nerve ischemia. Arch Ophthalmol 2000 Apr;118(4):533-536.
  7. Vorwerk CK, Naskar R, Dreyer EB. The excitotoxicity theory of glaucoma. Klin Monbl Augenheilkd 1999 Jan;214(1):2-11.
  8. Vorwerk CK, Naskar R, Schuettauf F, Quinto K, Zurakowski D, Gochenauer G, Robinson MB, Mackler SA, Dreyer EB. Depression of retinal glutamate transporter function leads to elevated intravitreal glutamate levels and ganglion cell death. Invest Ophthalmol Vis Sci 2000 Oct;41(11):3615-3621.
  9. Lagrèze WA, Otto T, Feuerstein TJ. Neuroprotection in ischemia of the retina in an animal model. Ophthalmologe 1999 Jun;96(6):370-374. (Ger).
  10. Abbasoglu, OE.; Kooner, KS. Future role of neuroprotective agents in glaucoma. In: Zimmermann TJ, ed. Textbook of ocular pharmacology. Philadelphia: Lippincott-Raven; 1997. p. 329-337.
  11. Chen Q, Moulder K, Tenkova T, Hardy K, Olney JW, Romano C. Excitotoxic cell death dependent on inhibitory receptor activation. Exp Neurol 1999 Nov;160(1):215-225.
  12. Lam TT, Abler AS, Tso MO. Apoptosis and caspases after ischemiareperfusion injury in rat retina. Invest Ophthalmol Vis Sci 1999 Apr;40(5):967-975.
  13. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-290.
  14. Yang DD, Kuan CY, Whitmarsh AJ, Rincón M, Zheng TS, Davis RJ, Rakic P, Flavell RA. Absence of excitotoxicityinduced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1997 Oct;389(6653):865-870.
  15. Kaur C, Foulds WS, Ling EA. Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol 2008 Dec;2(4):879-889.
  16. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci 2000 Dec;41(13): 4169-4174.
  17. Liu B, Neufeld AH. Nitric oxide sytahse-2 in human optic nerve head astrocytes induced by elevated pressure in vitro. Arch Ophthalmol 2001 Feb;119(2):240-245.
  18. Miller NR. The status of optic nerve degeneration and transplantation. Saudi J Ophthalmol 2000;14:1-14.
  19. Imai N, Tsuyama Y, Murayama K, Adachi-Usami E. Protective effect of nitric oxide on ischemic retina. Nihon Ganka Gakkai Zasshi 1997 Aug;101(8):639-643.
  20. Mizuno K, Koide T, Yoshimura M, Araie M. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Invest Ophthalmol Vis Sci 2001 Mar;42(3):688-694.
  21. Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia 2000 Oct;32(1):42-50.
  22. Ugolini G, Cremisi F, Maffei L. TrkA, TrkB and p75 mRNA expression is developmentally regulated in the rat retina. Brain Res 1995 Dec;704(1):121-124.
  23. Weber AJ, Harman CD, Viswanathan S. Effects of optic nerve injury, glaucoma and neuroprotection on the survival, structure and function of ganglion cells in the mammalian retina. J Physiol 2008 Sep;586(Pt 18):4393-4400.
  24. Kuehn MH, Fingert JH, Kwon YH. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies. Ophthalmol Clin North Am 2005 Sep;18(3):383-395.
  25. Johnson EC, Guo Y, Cepurna WO, Morrison JC. Neurotrophin roles in retinal ganglion cell survival: lessons from rat glaucoma models. Exp Eye Res 2009 Apr;88(4):808-815.
  26. Veach J. Functional dichotomy: glutathione and vitamin E in homeostasis relevant to primary open-angle glaucoma. Br J Nutr 2004 Jun;91(6):809-829.
  27. Schlötzer-Schrehardt U, Lommatzsch J, Küchle M, Konstas AG, Naumann GO. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open- angle glaucoma. Invest Ophthalmol Vis Sci 2003 Mar;44(3):1117-1125.
  28. Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy? Surv Ophthalmol 2007 Nov;(52 Suppl 2):162S-173S.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.